Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: GlobeNewswire
LEXINGTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, today announced the closing of its initial public offering of 6,900,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares, at a public offering price of $16.00 per share, for total gross proceeds of $110.4 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock were sold by Keros. Keros’ common stock began trading on the Nasdaq Global Market on April 8, 2020 under the symbol “KROS”. Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co. acted as joint book-running managers for the offering. H.C.
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROSPR Newswire
- An Investigation Has Commenced on Behalf of Keros Therapeutics, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your KROS LossesAccesswire
- Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Keros Therapeutics, Inc. (KROS) And Encourages Shareholders to Reach OutAccesswire
- Shareholder Rights Advocates at Levi & Korsinsky Investigate Keros Therapeutics, Inc. (KROS) Regarding Possible Securities Fraud ViolationsAccesswire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc. - KROS Accesswire
KROS
Earnings
- 11/6/24 - Miss
KROS
Sec Filings
- 12/12/24 - Form 8-K
- 12/10/24 - Form 8-K
- 12/3/24 - Form 8-K
- KROS's page on the SEC website